Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Academic performance evaluation in Asian children with ADHD treated with atomoxetine
2017-000740-18Phase 4
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: Correlation between change from baseline and 24-week endpoint in ADHDRS-IV-Parent:Inv total score and school grade average.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2017-000740-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000740-18.